| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2013.49.1514 |
| P698 | PubMed publication ID | 23775951 |
| P2093 | author name string | Lonneke V van de Poll-Franse | |
| Valery Lemmens | |||
| Floortje Mols | |||
| Gerard Vreugdenhil | |||
| Corina J van den Hurk | |||
| Tonneke Beijers | |||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colorectal cancer | Q188874 |
| colorectal carcinoma | Q25493920 | ||
| chemotherapy | Q974135 | ||
| quality of life | Q13100823 | ||
| P304 | page(s) | 2699-2707 | |
| P577 | publication date | 2013-06-17 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry | |
| P478 | volume | 31 |
| Q48454566 | 15th Annual Meeting of the Safety Pharmacology Society: Focus on traditional sensory systems |
| Q52610762 | 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. |
| Q49520475 | A Prospective Study of Chronic Oxaliplatin-Induced Neuropathy in Patients with Colon Cancer: Long-Term Outcomes and Predictors of Severe Oxaliplatin-Induced Neuropathy |
| Q38741208 | A Review of the Literature on Multiple Co-occurring Symptoms in Patients With Colorectal Cancer Who Received Chemotherapy Alone or Chemotherapy With Targeted Therapies |
| Q47629735 | A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve |
| Q57164771 | A practical guide to understanding, using and including patient reported outcomes in clinical trials in ovarian cancer |
| Q37631063 | A randomized exploratory phase 2 study in patients with chemotherapy-related peripheral neuropathy evaluating whole-body vibration training as adjunct to an integrated program including massage, passive mobilization and physical exercises |
| Q38204277 | A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration |
| Q53812330 | Acetyl-L-carnitine undervalued in the treatment of chemotherapy-induced peripheral neuropathy? |
| Q93136708 | Adjuvant chemotherapy in stage II-III operated colon cancer patients from a nontrial cohort in a low colon cancer prevalence country with predominant use of modified CAPOX |
| Q26782671 | American Cancer Society Colorectal Cancer Survivorship Care Guidelines |
| Q57157680 | An updated understanding of the mechanisms involved in chemotherapy-induced neuropathy |
| Q91778997 | Anxiety and depression mediate the association between chemotherapy-induced peripheral neuropathy and fatigue: Results from the population-based PROFILES registry |
| Q47967972 | Are chemotherapy-associated symptoms underestimated? A view beyond common toxicity criteria |
| Q61797229 | Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy |
| Q100760589 | Associations of the dietary World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) recommendations with patient-reported outcomes in colorectal cancer survivors 2-10 years post-diagnosis: a cross-sectional analysis |
| Q35925226 | Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice. |
| Q94220637 | Can External Use of Chinese Herbal Medicine Prevent Cumulative Peripheral Neuropathy Induced by Oxaliplatin? A Systematic Literature Review With Meta-analysis |
| Q93164128 | Cancer survivors who fully participate in the PROFILES registry have better health-related quality of life than those who drop out |
| Q36788256 | Candidate Predictors of Health-Related Quality of Life of Colorectal Cancer Survivors: A Systematic Review. |
| Q58455979 | Characterization and diagnostic evaluation of chronic polyneuropathies induced by oxaliplatin and docetaxel comparing skin biopsy to quantitative sensory testing and nerve conduction studies |
| Q38773529 | Chemotherapy-Induced Neuropathy in Cancer Survivors |
| Q53549443 | Chemotherapy-induced peripheral neuropathy (CIPN) and vitamin B12 deficiency. |
| Q38208769 | Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review |
| Q46560517 | Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry. |
| Q41069484 | Chemotherapy-induced peripheral neuropathy, physical activity and health-related quality of life among colorectal cancer survivors from the PROFILES registry. |
| Q27010318 | Chemotherapy-induced peripheral neurotoxicity: a critical analysis |
| Q47569311 | Chemotherapy-related neuropathic symptom management: a randomized trial of an automated symptom-monitoring system paired with nurse practitioner follow-up. |
| Q47894849 | Chronic Pain and Neuropathy Following Adjuvant Chemotherapy |
| Q51742090 | Chronic disease management perspectives of colorectal cancer survivors using the Veterans Affairs healthcare system: a qualitative analysis. |
| Q36162504 | Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance). |
| Q43172077 | Comment on: 'Subgroup effects in a randomized trial of different types and doses of exercise during breast cancer chemotherapy'. |
| Q33711444 | Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). |
| Q88236353 | Course of chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer patients: A longitudinal study |
| Q38254351 | Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review. |
| Q33711656 | Disease burden and pain in obese cancer patients with chemotherapy-induced peripheral neuropathy |
| Q36350645 | Effect of Vitamin E on Oxaliplatin-induced Peripheral Neuropathy Prevention: A Randomized Controlled Trial |
| Q90075055 | Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical Trial |
| Q33561260 | Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients |
| Q47266458 | Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial. |
| Q50269461 | Eight-week, multimodal exercise counteracts a progress of chemotherapy-induced peripheral neuropathy and improves balance and strength in metastasized colorectal cancer patients: a randomized controlled trial |
| Q89577629 | Emotional distress and quality of life during folinic acid, fluorouracil, and oxaliplatin in colorectal cancer patients with and without chemotherapy-induced peripheral neuropathy: A cross-sectional study |
| Q40151854 | Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20). |
| Q37408810 | Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients |
| Q57122383 | Extent of enhancement on multiphase contrast-enhanced CT images is a potential prognostic factor of stage I-III colon cancer |
| Q57474121 | Factors Associated with New Persistent Opioid Usage After Lung Resection |
| Q38707400 | Factors associated with the development and severity of oxaliplatin-induced peripheral neuropathy: a systematic review |
| Q38740918 | Falls, Functioning, and Disability Among Women With Persistent Symptoms of Chemotherapy-Induced Peripheral Neuropathy |
| Q51732172 | Impact of physical exercise in cancer survivors during and after antineoplastic treatments. |
| Q85623151 | Is the benefit of oxaliplatin in rectal cancer clinically relevant? |
| Q90247055 | JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer |
| Q37662576 | Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review. |
| Q58104326 | Long-term Outcomes After Surgery Involving the Pelvic Floor in Rectal Cancer: Physical Activity, Quality of Life, and Health Status |
| Q58874339 | Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study |
| Q57067804 | Markers of Mitochondrial Metabolism in Tumor Hypoxia, Systemic Inflammation, and Adverse Outcome of Rectal Cancer |
| Q36117942 | Measuring Therapy-Induced Peripheral Neuropathy: Preliminary Development and Validation of the Treatment-Induced Neuropathy Assessment Scale |
| Q38660867 | Multicenter, cross-sectional observational study of the impact of neuropathic pain on quality of life in cancer patients. |
| Q28270819 | Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: A systematic review |
| Q49088651 | Neoadjuvant chemotherapy in locally advanced colon cancer. A phase II trial |
| Q35002187 | Neuropathic symptoms, quality of life, and clinician perception of patient care in medical oncology outpatients with colorectal, breast, lung, and prostate cancer |
| Q44349937 | New Persistent Opioid Use Among Patients With Cancer After Curative-Intent Surgery |
| Q88324958 | Opioid Prescribing After Curative-Intent Surgery: A Qualitative Study Using the Theoretical Domains Framework |
| Q39289330 | Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial |
| Q38338989 | Outcomes and endpoints in cancer trials: bridging the divide |
| Q47670602 | Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life |
| Q88603422 | Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer |
| Q48192466 | Pain in Platin-Induced Neuropathies: A Systematic Review and Meta-Analysis |
| Q54960570 | Pain in cancer survivors. |
| Q48067734 | Patient-reported outcomes in long-term survivors of metastatic colorectal cancer needing liver resection |
| Q40990625 | Perception of social exclusion, neuropathy, and quality of life among Hansen's disease patients |
| Q39095046 | Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry |
| Q50002199 | Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx®): a placebo-controlled randomised phase II study (PLIANT). |
| Q39796533 | Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy |
| Q48070035 | Physical impairments and quality of life of colorectal cancer survivors: a case-control study |
| Q51147046 | Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer. |
| Q93073304 | Prevalence and Predictors of Cisplatin-Induced Peripheral Neuropathy at the Kenyatta National Hospital |
| Q38931361 | Preventing oxaliplatin-induced neurotoxicity: rationale and design of phase Ib randomized, double-blind, placebo-controlled, cross-over trials for early clinical evaluation of investigational therapeutics. |
| Q35331858 | Prevention of oxaliplatin-induced peripheral neuropathy by a polyamine-reduced diet-NEUROXAPOL: protocol of a prospective, randomised, controlled, single-blind and monocentric trial. |
| Q37098312 | Prognostic and predictive value of extended RAS mutation and mismatch repair status in stage III colorectal cancer |
| Q52591943 | Psychometric Testing of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale Using Pooled Chemotherapy-Induced Peripheral Neuropathy Outcome Measures St |
| Q89338392 | Rechallenge with oxaliplatin and peripheral neuropathy in colorectal cancer patients |
| Q34536680 | Reliability and validity of a survey to measure bowel function and quality of life in long-term rectal cancer survivors |
| Q94686663 | Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy |
| Q55437025 | Sigma-1 receptor: a new player in neuroprotection against chemotherapy-induced peripheral neuropathy. |
| Q28088348 | Surveillance and Survivorship after Treatment for Colon Cancer |
| Q89447091 | Symptom Experiences in Colorectal Cancer Survivors After Cancer Treatments: A Systematic Review and Meta-analysis |
| Q89562004 | Systematic review of clinical practice guidelines for colorectal and anal cancer: the extent of recommendations for managing long-term symptoms and functional impairments |
| Q39763516 | The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling. |
| Q47293439 | The Content Validity of a Chemotherapy-Induced Peripheral Neuropathy Patient-Reported Outcome Measure |
| Q91605038 | The Impact of Education and Prescribing Guidelines on Opioid Prescribing for Breast and Melanoma Procedures |
| Q89795078 | The Treatment-induced Neuropathy Assessment Scale (TNAS): a psychometric update following qualitative enrichment |
| Q37031281 | The effect of n-3 polyunsaturated fatty acids on incidence and severity of oxaliplatin induced peripheral neuropathy: a randomized controlled trial |
| Q90599921 | The effect of pregabalin and duloxetine treatment on quality of life of breast cancer patients with taxane-induced sensory neuropathy: A randomized clinical trial |
| Q35898310 | The experience of chemotherapy-induced peripheral neuropathy in adult cancer patients: a qualitative thematic synthesis. |
| Q50041663 | The hard road to data interpretation: three or six months of adjuvant chemotherapy for patients with stage III colon cancer? |
| Q41499485 | The impact of diabetes on neuropathic symptoms and receipt of chemotherapy among colorectal cancer patients: results from the PROFILES registry |
| Q38700984 | The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice |
| Q53145460 | The trajectory of neurotoxic side effects' impact on daily life: a qualitative study. |
| Q34433406 | Therapeutic strategies for cancer treatment related peripheral neuropathies |
| Q38228522 | Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. |
| Q50089791 | Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715). |
| Q26771423 | Whole-Body Vibration as a Modality for the Rehabilitation of Peripheral Neuropathies: Implications for Cancer Survivors Suffering from Chemotherapy-Induced Peripheral Neuropathy |
| Q33824948 | [EXPRESS] Ion channels and neuronal hyperexcitability in chemotherapy-induced peripheral neuropathy; cause and effect? |
Search more.